Check-Cap (NASDAQ:MBAI) Stock Price Down 0.7% – Here’s Why

Check-Cap Ltd (NASDAQ:MBAIGet Free Report)’s stock price was down 0.7% on Thursday . The company traded as low as $8.33 and last traded at $8.83. Approximately 57,301 shares traded hands during mid-day trading, a decline of 37% from the average session volume of 91,578 shares. The stock had previously closed at $8.89.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Check-Cap in a research note on Tuesday, July 21st. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

Read Our Latest Stock Report on MBAI

Check-Cap Price Performance

The firm has a market cap of $83.53 million, a price-to-earnings ratio of -4.39 and a beta of 0.68. The company has a fifty day moving average price of $8.36 and a two-hundred day moving average price of $10.63.

About Check-Cap

(Get Free Report)

Check-Cap Ltd. (NASDAQ: MBAI) is an Israel-based medical technology company focused on non-invasive screening solutions for colorectal cancer. The company develops an ingestible imaging capsule and associated detection system intended to provide a patient-friendly alternative to traditional colonoscopy and CT colonography for colorectal screening and polyp detection.

Check-Cap’s technology centers on a swallowable capsule that acquires images of the colon as it traverses the gastrointestinal tract; external detectors capture the transmitted signals and software reconstructs images for clinical review.

Further Reading

Receive News & Ratings for Check-Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check-Cap and related companies with MarketBeat.com's FREE daily email newsletter.